BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

BioNTech (BNTX) stock fell 8.3% after terminating a Phase 2 cancer trial due to survival imbalance. The setback follows recent optimism in the neoantigen vaccine space and raises concerns about its oncology pipeline. The FDA's anticipated COVID-19 vaccine approval did not offset investor worries.

BioNTech SE (BNTX) shares dropped 10% after terminating a Phase 2 cancer trial due to efficacy concerns. The trial, testing autogene cevumeran for colorectal cancer, was halted based on a DSMB recommendation. No safety issues were found. The company plans to analyze the data and share insights. Other trials, like IMcode003 for pancreatic cancer, continue. According to BioNTech, the decision was made after the futility boundary was crossed in October 2025.

The FDA approved COVID-19 vaccines from Pfizer, Moderna, and Sanofi targeting the XFG strain. Pfizer and Moderna's vaccines use mRNA technology, while Sanofi's does not. The approval covers individuals aged 65+ and those with underlying conditions. The CDC reports low vaccine uptake and increasing infections in 47 states.

FDA approved updated COVID-19 vaccines for adults 65+, younger high-risk individuals, and children (age varies by vaccine). Eligibility includes conditions like asthma, diabetes, and obesity. Pharmacy access and insurance coverage may vary. The CDC and experts recommend vaccination in October, with COVID still posing health risks.

Moderna and Merck reported success in a late-stage trial of their mRNA cancer vaccine for melanoma, marking a breakthrough after over a century of failed attempts. The vaccine, personalized for each patient, showed efficacy in preventing tumor recurrence. Wall Street estimates potential sales in the billions. Merck faces Keytruda patent expiration, while Moderna seeks new growth avenues. Both companies plan further trials and data analysis. Moderna's shares surged over 130% post-announcement.

The FDA approved updated Covid-19 vaccines from Moderna, Novavax-Sanofi, and Pfizer-BioNTech on August 27, targeting the dominant XFG variant. The companies can now ship doses to pharmacies and doctors' offices, according to their statements.